VOTING AGREEMENTVoting Agreement • July 11th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of July 10, 2023, by and among Aceragen, Inc., a Delaware corporation (together with its subsidiaries, “Aceragen”) and [●], a stockholder of Aceragen listed on Schedule A hereto (the “Securityholder”).
BRIDGE FUNDING AGREEMENTBridge Funding Agreement • July 11th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • New York
This Bridge Funding Agreement (this “Agreement”) is entered into as of July 11, 2023 (the “Effective Date”), between Aceragen, Inc., a Delaware corporation with a principal place of business at 505 Eagleview Boulevard, Suite 212, Exton, PA 19341 (“Aceragen”), and NovaQuest Co-Investment Fund XV, L.P., a Delaware limited partnership, with a place of business at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”). Aceragen (and its successors in interest) and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
SECURITY AGREEMENTSecurity Agreement • July 11th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • New York
THIS SECURITY AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time, this “Security Agreement”) is entered into as of July 11, 2023, by Aceragen, Inc., a Delaware corporation (“Aceragen” and together with any additional obligors joined as parties hereto, collectively, “Grantor”), and NovaQuest Co-Investment Fund XV, L.P., a Delaware limited partnership (“Secured Party”).
